Answers are grounded in this paper and cite their sources.
Background Although metronidazole is no longer recommended as first-line therapy for Clostridioides difficile infection (CDI), its use persists. Heme-dependent metronidazole resistance has recently been linked to the PnimBG promoter mutation. We investigated the occurrence of this determinant in clinical C. difficile isolates and evaluated ready-to-use culture media for detecting metronidazole resistance.Materials and Methods Seventy-five C. difficile isolates carrying PnimBG and/or nimB coding mutations, together with 10 wild-type isolates, were analysed. Metronidazole susceptibility was determined by E-test on ready-to-use Chocolate agar (CA), Fastidious Anaerobe Agar (FAA), and freshly prepared Brain Heart Infusion agar (BHI) with and without 5 mg/L hemin. Resistance was defined as MIC >2 mg/L.Results All isolates were susceptible on BHI without hemin. Isolates carrying PnimBG alone remained susceptible on all media. Heme-dependent resistance was associated with the combined presence of PnimBG and nimB coding mutations but varied by medium. CA and BHI with hemin showed comparable performance, whereas FAA substantially underestimated resistance.Conclusion Our data show that heme-dependent metronidazole resistance in C. difficile was associated with both the PnimBG promoter mutation and specific nimB coding mutations. Ready-to-use FAA substantially underestimates resistance, and clinical laboratories should consider using ready-to-use CA and freshly prepared BHI with hemin for metronidazole susceptibility testing in C. difficile to avoid false susceptible classification.
No takes yet. Share an insight, caveat, or question.
Zikova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: